> ## Documentation Index
> Fetch the complete documentation index at: https://docs.hi-doctor.ai/llms.txt
> Use this file to discover all available pages before exploring further.

# Oral minoxidil — off-label hair-loss option

> Oral minoxidil for hair loss: how it differs from the topical solution, why the tablet form is off-label in the EU, and what trials reported.

Minoxidil comes in two very different forms, and the difference matters. The liquid or foam rubbed into the scalp is a properly authorised medicine for male pattern hair loss in EU countries. Minoxidil also exists as a tablet, but in the EU those tablets are only licensed as a blood-pressure medicine — taking low-dose minoxidil tablets for hair is off-label, meaning a doctor prescribes it outside its licensed use.

## What is oral minoxidil?

Minoxidil is a potassium-channel opener and vasodilator, available as a scalp solution or foam, or as a tablet. It is authorised for androgenetic alopecia in adults in its topical form; the tablet for hair loss is off-label.

<Info>
  Active ingredient: minoxidil. Dosages: 5% topical, or 2.5–5 mg oral.
</Info>

## How it works

<CardGroup cols={3}>
  <Card title="Minoxidil opens potassium channels" icon="atom">
    Minoxidil acts on ATP-sensitive potassium channels.
  </Card>

  <Card title="Blood flow around follicles rises" icon="droplet">
    Applied to the scalp, it widens small blood vessels around hair follicles.
  </Card>

  <Card title="The growing phase lasts longer" icon="seedling">
    It appears to keep hair follicles in their growing (anagen) phase for longer and increases hair diameter, although exactly how it acts on hair is still not fully understood. Topical is the standard treatment in mild-to-moderate androgenetic alopecia; low-dose oral — off-label, under medical supervision — is an alternative when adherence to topical is poor or the response is insufficient.
  </Card>
</CardGroup>

## EU authorisation

Topical minoxidil has been authorised for use in the EU since 1 May 1988. EU-authorised minoxidil **tablets** are indicated only for severe, treatment-resistant high blood pressure, and their product information states they must never be used alone or as initial therapy — always alongside a beta-blocker and a diuretic. None of that licensed dosing framework applies to the low doses used off-label for hair loss. Oral minoxidil for hair is a route of administration, not a brand: it means minoxidil taken as a tablet rather than applied to the scalp, and any such use is a decision for the prescribing doctor.

## What the studies reported

<Note>
  Results below are grouped by source and evidence grade so journal data and observational figures are not confused. A trial in men aged 18–49 with vertex-pattern loss ran for 48 weeks, so it does not establish results beyond one year or in other patterns of hair loss.
</Note>

<Tabs>
  <Tab title="Oral vs topical, randomised">
    In a 24-week randomised trial of oral minoxidil 5 mg versus topical minoxidil 5% (n=45 per arm): unwanted hair growth away from the scalp (hypertrichosis) occurred in 22/45 (49%) on the oral drug versus 11/45 (25%) on topical (P=.02); headache in 6/45 (14%) versus 1/45 (2%) (P=.046); scalp eczema was more frequent with topical, 7/45 (16%) versus 1/45 (2%).
  </Tab>

  <Tab title="Oral, observational series">
    In a retrospective multicentre study of 1,404 patients treated for at least 3 months, the most frequent adverse effect was hypertrichosis (15.1%, causing withdrawal in 0.5%). Systemic effects: lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital oedema 0.3%, insomnia 0.2% — leading to discontinuation in 1.2% of patients.
  </Tab>
</Tabs>

<AccordionGroup>
  <Accordion title="Sources">
    * AEMPS CIMA — Regaxidil 20 mg/ml solución cutánea, ficha técnica (Spain, registration 57597, authorised 1 May 1988)
    * AEMPS CIMA — Regaine 50 mg/g espuma cutánea, ficha técnica (Spain, registration 76483)
    * AEMPS CIMA — Loniten 10 mg comprimidos, ficha técnica (Spain, registration 55636) — oral minoxidil, severe hypertension only
    * AEMPS CIMA — Minogal 2,5/5/10 mg comprimidos EFG, ficha técnica (Spain, registration 91045–91047, authorised 2026) — oral minoxidil, severe resistant hypertension only
    * Olsen et al., *J Am Acad Dermatol* 2002;47(3):377–385 (PMID 12196747)
    * Penha MA, Miot HA, Kasprzak M, Muller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. *JAMA Dermatol.* 2024;160(6):600–605 (PMID 38598226)
    * Vañó-Gálván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1,404 patients. *J Am Acad Dermatol.* 2021;84(6):1644–1651 (PMID 33639244)
  </Accordion>
</AccordionGroup>

## What has been reported

| Effect                                                      | Topical (EU product information)       | Oral tablet                                        |
| ----------------------------------------------------------- | -------------------------------------- | -------------------------------------------------- |
| Scalp itching, dermatitis, acneiform dermatitis, rash       | Common                                 | —                                                  |
| Hypertrichosis (hair growth away from the scalp)            | Common, including facial hair in women | 15.1%–49% depending on the study                   |
| Headache                                                    | —                                      | Common (label); 0.4%–14% in studies above          |
| Breathlessness (dyspnoea)                                   | —                                      | Common                                             |
| Dizziness, nausea, peripheral oedema                        | —                                      | Uncommon                                           |
| Palpitations, tachycardia, chest pain                       | —                                      | Rare; 0.9% tachycardia in the observational series |
| Low blood pressure, allergic reactions including angioedema | —                                      | Not known                                          |
| Temporary increased shedding                                | Not known                              | —                                                  |

## Who it is not suitable for

The tablet's label warns about fluid retention and fluid around the heart. It is otherwise reserved, in its licensed form, for severe treatment-resistant high blood pressure that has not responded to previous treatment, always alongside a beta-blocker and a diuretic — a framework that does not apply to off-label hair-loss dosing.

<Warning>
  For severe, sudden or unexpected symptoms — palpitations, chest pain, breathlessness at rest, fainting or rapid swelling — seek urgent care.
</Warning>

## How Hi-Doctor handles it

Minoxidil is prescribed topically twice a day, or as a tablet once daily if the doctor decides that route is appropriate. It combines well with finasteride or dutasteride. For dose-schedule detail, blood-pressure and pulse monitoring, and what extra body hair means for you, see the [low-dose oral minoxidil guide](https://hi-doctor.ai/guides/oral-minoxidil).

## Common questions

<AccordionGroup>
  <Accordion title="How long does oral minoxidil take to work for hair loss?">
    Oral minoxidil for hair loss is gradual. The first changes may be seen at months 2 to 4. Early shedding can occur, and photographs taken in the same light are more useful than day-to-day checking. The doctor normally reviews tolerance and progress after several months.
  </Accordion>

  <Accordion title="Is oral minoxidil approved for hair loss in the EU?">
    EU-authorised minoxidil tablets are indicated only for severe, treatment-resistant high blood pressure. Taking low-dose minoxidil tablets for hair is off-label, meaning a doctor prescribes it outside its licensed use. The topical form is properly authorised for hair loss.
  </Accordion>

  <Accordion title="What are the side effects of oral minoxidil for hair loss?">
    Extra facial or body hair is common with systemic exposure (15.1% in a large observational series). Headache, dizziness, palpitations, ankle swelling and fluid retention can occur. Rare but serious heart or breathing symptoms need urgent assessment — seek urgent care for chest pain, fainting or breathlessness at rest.
  </Accordion>

  <Accordion title="Can I take oral minoxidil with finasteride or dutasteride?">
    Yes. Oral minoxidil combines well with finasteride or dutasteride, and this combination is commonly used in hair-loss treatment. A doctor decides whether this combination is appropriate for you after reviewing your case.
  </Accordion>

  <Accordion title="What happens if I stop taking oral minoxidil?">
    Hair loss returns within 3 to 6 months after stopping minoxidil, whether oral or topical. The effect depends on continuous use — discuss any plan to stop with your doctor.
  </Accordion>
</AccordionGroup>

Related: [postpartum hair loss](/library/conditions/postpartum-hair-loss), one of the conditions minoxidil is considered for. See also [androgenetic alopecia](/library/conditions/androgenetic-alopecia), [safety and eligibility checks](/essentials/safety), [how the consultation works](/essentials/how-it-works) and [pricing](/essentials/pricing).

## Start a consultation

<Card title="Hair-growth consultation" icon="stethoscope" href="https://hi-doctor.ai/consultation/hair-growth/1">
  Answer the hair-growth questionnaire and a registered doctor reviews it.
  They decide whether treatment is appropriate, which one, and at what dose —
  and declining is a normal outcome. See [what it costs](/essentials/pricing)
  and [how the review works](/essentials/how-it-works).
</Card>

<Warning>
  This page is reference information, not medical advice and not a prescription.
  Whether a medicine is appropriate for you is decided by a registered doctor
  after reviewing your consultation.
</Warning>